Welcome to our dedicated page for DOCGO SEC filings (Ticker: DCGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DocGo Inc. filings document the company’s mobile health, medical transportation and virtual care business, along with formal disclosures on operating results, governance, listing compliance and capital allocation. Form 8-K reports include quarterly and annual earnings releases, non-GAAP measures such as adjusted gross margin and adjusted EBITDA contribution margin, share repurchase program disclosures, and Nasdaq minimum bid price compliance matters.
Proxy materials cover director elections, advisory executive compensation votes and capital-structure proposals. Other filings record board and committee changes, special committee formation, shareholder voting matters, material-event disclosures and common-stock structure for the Nasdaq-listed issuer.
DocGo Inc. director James M. Travers reported a new equity award from the company. On December 12, 2025, he was granted 150,000 restricted stock units (RSUs) of DocGo common stock under the issuer’s 2021 Stock Incentive Plan at a price of $0 per unit.
Each RSU represents the right to receive one share of common stock upon vesting on December 12, 2026, subject to the plan’s terms. Following this grant, Travers beneficially owns 240,999 shares of DocGo stock directly and 391,028 shares indirectly through Travers Holdings LLC, over which he and Susan D. Travers share voting and dispositive power while each disclaiming beneficial ownership of those securities except to the extent of any pecuniary interest.
DocGo Inc. extended the expiration date of its existing share repurchase program from December 31, 2025 to June 30, 2026. The program continues to authorize the company to repurchase up to $26 million of its common stock.
DocGo may buy shares from time to time through open-market purchases, privately negotiated transactions, or arrangements such as Rule 10b5-1 trading plans and accelerated share repurchase programs, during trading windows when it is not in possession of material non-public information. Repurchases may be funded with existing cash and cash equivalents, future cash flow, or proceeds of borrowings or debt offerings, and the program can be modified, suspended, or discontinued at any time.
DocGo (DCGO) reported a sharp year-over-year contraction in Q3 2025. Revenue was $70.8M versus $138.7M a year ago, driven by a steep drop in Mobile Health Services to $20.7M from $90.7M, while Transportation Services delivered $50.1M vs $48.0M. The company posted a net loss attributable to stockholders of $27.8M compared with $5.5M income a year earlier, reflecting lower volume and non-cash charges.
Management recorded a $8.7M goodwill impairment tied to the Rapid Temps reporting unit and a $8.0M impairment of finite‑lived intangibles in Mobile Health Services. For the nine months, revenue was $247.3M vs $495.7M, with a $48.3M loss to stockholders. Cash from operations was $44.9M, supported by a large reduction in accounts receivable. The balance sheet showed cash and cash equivalents of $73.4M, total assets of $353.8M, and no outstanding line of credit at quarter‑end. Shares outstanding were 97,813,372 as of November 7, 2025.
DocGo Inc. (DCGO) furnished its earnings materials for the quarter ended September 30, 2025. The company issued a press release and provided supplemental non-GAAP metrics, including adjusted gross margin and adjusted EBITDA contribution margin, as supporting materials.
Management scheduled a conference call and webcast at 5:00 p.m. Eastern Time on November 10, 2025 to discuss results. The materials were furnished, not filed, and include Exhibit 99.1 (Press Release) and Exhibit 99.2 (Non-GAAP Financial Information).
DocGo Inc. filed an amended Form 8‑K to attach the Merger Agreement for its completed acquisition of SteadyMD, Inc. via subsidiary Ambulnz Holdings, LLC. The transaction totals up to $25 million, consisting of $12.5 million in cash paid at closing and up to $12.5 million as a contingent earn‑out payable in cash or equity at the Company’s election, tied to performance conditions. The closing payment is subject to customary post‑closing adjustments for working capital, debt, and transaction expenses.
Upon filing a Certificate of Merger on October 20, 2025, SteadyMD merged into STMD Merger Company, LLC, which survived; all shares, options, and warrants of the Acquired Company were canceled. This amendment adds the Merger Agreement as Exhibit 2.1 and does not change other prior disclosures.
DocGo Inc. announced that its wholly owned subsidiary, Ambulnz Holdings, completed the acquisition of SteadyMD, Inc. via a merger on October 20, 2025. The deal carries an aggregate purchase price of up to $25 million, including $12.5 million in cash paid at closing and up to $12.5 million in contingent earn-out, payable in cash or equity at the company’s election if specified performance conditions are met. The closing cash amount is subject to customary post‑closing adjustments for working capital, indebtedness, and transaction expenses.
Upon filing the certificate of merger, SteadyMD merged into a DocGo subsidiary with the subsidiary surviving, and all SteadyMD shares, options, and warrants were canceled under the agreement. DocGo will host a conference call and webcast on October 21, 2025 at 11:00 a.m. ET to discuss the transaction.
Stephen K. Klasko, a director of DocGo Inc. (DCGO), was granted 100,000 restricted stock units (RSUs) under the Issuer's 2021 Stock Incentive Plan. Each RSU represents the right to receive one share of DocGo common stock upon vesting.
The RSUs vest on September 10, 2026 subject to the terms of the plan. The reported grant carried a $0 per-share price and, after the grant, Mr. Klasko is reported to beneficially own 115,000 shares. The Form 4 was submitted by an attorney-in-fact on behalf of the reporting person.